What is the average price target for INMUNE BIO INC (INMB) stock?
10 analysts have analysed INMB and the average price target is 7.14 USD. This implies a price increase of 372.85% is expected in the next year compared to the current price of 1.51.
INMUNE BIO INC (INMB) Forecast, Price Target & Analyst Ratings
NASDAQ:INMB • US45782T1051
Current stock price
1.51 USD
+0.08 (+5.59%)
At close:
1.46 USD
-0.05 (-3.31%)
After Hours:
Analyst forecast overview
View the latest analyst price targets, stock forecast, EPS estimates, revenue projections, revisions, full estimates, rating distribution and upgrades/downgrades for INMUNE BIO INC (INMB).
Forecast Snapshot
Next Earnings Forecast
Earnings Estimate- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.21
- Revenue Estimate
Price Target Details & History
Consensus Price Target and Range
Mean target
$7.14
Upside
+ 372.85%
From current price of $1.51 to mean target of $7.14, Based on 10 analyst forecasts
Low
$4.04
Median
$7.65
High
$9.45
Price Target Revisions
1 Month
33.33%
3 Months
33.33%
Price Target Summary
10 Wall Street analysts provided a forecast for the next 12 months for INMB. The average price target is 7.14 USD. This implies a price increase of 372.85% is expected in the next year compared to the current price of 1.51.
The average price target has been revised upward by 33.33% in the past 3 months.
Analyst Ratings & History
Current Analyst Ratings
Analyst Ratings History
Analyst Ratings Consensus
ChartMill Buy Consensus
82.00%
INMB was analyzed by 10 analysts. The buy percentage consensus is at 82. So analysts seem to be very confident about INMB.
In the previous month the buy percentage consensus was at a similar level.
INMB was analyzed by 10 analysts. More opinions would make the average more meaningful.
Recent Upgrades & Downgrades
| Date | Firm | Action | From → To |
|---|---|---|---|
| 2026-03-11 | LUCID CAPITAL MARKETS | Upgrade | Neutral -> Buy |
| 2025-07-02 | Maxim Group | Maintains | Buy -> Buy |
| 2025-07-01 | ScotiaBank | Downgrade | Sector Outperform -> Sector Underperform |
| 2025-07-01 | BTIG | Downgrade | Buy -> Neutral |
| 2025-02-13 | Maxim Group | Maintains | Buy -> Buy |
| 2025-02-11 | ScotiaBank | Maintains | Sector Outperform -> Sector Outperform |
| 2024-10-21 | Alliance Global Partners | Initiate | Buy |
| 2024-09-27 | Raymond James | Initiate | Outperform |
| 2024-08-22 | ScotiaBank | Initiate | Sector Outperform |
| 2023-06-01 | Baird | Initiate | Outperform |
| 2022-05-24 | BTIG | Maintains | Buy |
| 2022-05-24 | B. Riley Securities | Downgrade | Buy -> Neutral |
| 2022-01-24 | B. Riley Securities | Maintains | Buy |
| 2021-04-21 | B. Riley FBR | Initiate | Buy |
Next Earnings Forecast Details
Next Earnings Details
- Release Date
- May 6, 2026
- Period
- Q1 / 2026
- EPS Estimate
- -$0.21
- Revenue Estimate
- Revenue Q2Q
- -100.00%
- EPS Q2Q
- 51.77%
- Number of Analysts
- 6
Next Earnings Revisions
Revenue (1 Month)
N/A
Revenue (3 Months)
N/A
EPS (1 Month)
19.74%
EPS (3 Months)
5.43%
Next Earnings Summary
INMB is expected to report earnings on 5/6/2026. The consensus EPS estimate for the next earnings is -0.21 USD and the consensus revenue estimate is 0 USD.
Full Analyst Estimates 2026 - 2033
Yearly Earnings Per Share (EPS), Revenue, EBIT, EBITDA and Operating Margin Analyst Estimates
| 2023 | 2024 | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY % growth | 155K -58.11% | 14K -90.97% | 50K 257.14% | -100.00% | 6.487M | 25.562M 294.05% | 98.486M 285.28% | 171.96M 74.60% | 253.65M 47.51% | 336.29M 32.58% | 383.81M 14.13% | |
| EBITDA YoY % growth | N/A | N/A | -30.785M | N/A | N/A | N/A | N/A | N/A | N/A | N/A | N/A | |
| EBIT YoY % growth | -29.741M -14.61% | -42.635M -43.35% | -30.869M 27.60% | -31.414M -1.77% | -36.42M -15.93% | -33.486M 8.06% | 36.276M 208.33% | 89.286M 146.13% | 168.15M 88.33% | 239.52M 42.44% | 284.36M 18.72% | |
| Operating Margin | -19,187.74% | -304,535.71% | -61,738.00% | N/A | -561.43% | -131.00% | 36.83% | 51.92% | 66.29% | 71.22% | 74.09% | |
| EPS YoY % growth | -1.67 -9.87% | -2.11 -26.35% | -1.92 9.00% | -0.87 54.84% | -0.90 -3.92% | -0.46 48.49% | 1.03 321.98% | 2.54 146.53% | 4.75 87.15% | 6.74 41.85% | 7.58 12.41% |
All data in USD
Quarterly Earnings Per Share (EPS), Revenue, EBIT and EBITDA Analyst Estimates
| Q1 / 26 | Q2 / 26 | Q3 / 26 | Q4 / 26 | |
|---|---|---|---|---|
| EPS Q2Q % growth | -0.21 51.77% | -0.19 81.54% | -0.19 19.25% | -0.19 4.80% |
| Revenue Q2Q % growth | -100.00% | |||
| EBITDA Q2Q % growth | N/A | N/A | N/A | N/A |
| EBIT Q2Q % growth | -6.293M 36.46% | -6.591M 18.20% | -7.283M 2.02% | -7.458M -36.24% |
All data in USD
Yearly Earnings Per Share (EPS) and Revenue Trends vs Historical Data
Long Term Forward Growth Forecast Summary
Long Term EPS Growth (CAGR)
EPS Next 3 Year
20.70%
EPS Next 5 Year
27.15%
Long Term Revenue Growth (CAGR)
Revenue Next 3 Year
637.40%
Revenue Next 5 Year
385.50%
Long Term EBIT Growth (CAGR)
EBIT Next 3 Year
N/A
EBIT Next 5 Year
N/A
INMUNE BIO INC / INMB Forecast FAQ
What is the next earnings date for INMB stock?
INMUNE BIO INC (INMB) will report earnings on 2026-05-06.
Can you provide the consensus estimates for INMUNE BIO INC next earnings?
The consensus EPS estimate for the next earnings of INMUNE BIO INC (INMB) is -0.21 USD and the consensus revenue estimate is 0 USD.
What is the expected long term growth rate for INMUNE BIO INC (INMB)?
The expected long term growth rate for INMUNE BIO INC (INMB) is 637.4%.